Biochem/physiol Actions
NLX-112 (also known as befiradol or F13640) is a highly selective 5-HT1A receptor full agonist with >1000-fold selectivity compared to other types of receptors. It has been investigated for the treatment of Parkinson′s disease patients who exhibit L-DOPA-induced dyskinesia
This product has met the following criteria to qualify for the following awards: